Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Indication, By Vector Type, By Route Of Administration, By Region, And Segment Forecasts, 2025

The global cancer gene therapy market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.34% from 2025 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine.
The gene induced immunotherapy segment held the largest share in 2024 due to increase in the advancement in gene induced immunotherapy research.
Biopharmaceutical companies held the largest market share in 2024 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field.
North America dominated the market in 2024 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region.

Product Code: GVR-4-68039-984-2

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
- 1.2.1. Indication
- 1.2.2. Route of Administration
- 1.2.3. Vector Type
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
- 1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Rising prevalence of cancer
  - 3.2.1.2. Advancements in gene therapy technology
  - 3.2.1.3. Increasing adopton of personalized medicine
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. High costs of treatment
3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gene Therapy Market: Indication Business Analysis

4.1. Indication Segment Dashboard
4.2. Global Cancer Gene Therapy Market Indication, Movement Analysis
4.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
4.4. Large B-Cell Lymphoma
- 4.4.1. Global Large B-Cell Lymphoma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Multiple Myeloma
- 4.5.1. Global Multiple Myeloma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Acute Lymphoblastic Leukemia (ALL)
- 4.6.1. Global Acute Lymphoblastic Leukemia (ALL) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Melanoma (lesions)
- 4.7.1. Global Melanoma (lesions) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
- 4.8.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: Route of Administration Business Analysis

5.1. Route of Administration Segment Dashboard
5.2. Global Cancer Gene Therapy Market Route of Administration Movement Analysis
5.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Intravenous
- 5.4.1. Global Intravenous Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Others
- 5.5.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: VectorType Business Analysis

6.1. Vector Type Segment Dashboard
6.2. Global Cancer Gene Therapy Market Vector Type Movement Analysis
6.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Vector Type, 2018 to 2030 (USD Million)
6.4. Lentivirus
- 6.4.1. Global Lentivirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. RetroVirus & gamma RetroVirus
- 6.5.1. Global RetroVirus & gamma RetroVirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. AAV
- 6.6.1. Global AAV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Modified Herpes Simplex Virus
- 6.7.1. Global Modified Herpes Simplex Virus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Adenovirus
- 6.8.1. Global Adenovirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Others
- 6.9.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Indication, Route of Administration, & Vector Type

7.1. Regional Dashboard
7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
7.3. North America
- 7.3.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Competitive Scenario
  - 7.3.2.3. Regulatory Framework
  - 7.3.2.4. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Competitive Scenario
  - 7.3.3.3. Regulatory Framework
  - 7.3.3.4. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. Mexico
  - 7.3.4.1. Key Country Dynamics
  - 7.3.4.2. Competitive Scenario
  - 7.3.4.3. Regulatory Framework
  - 7.3.4.4. Mexico Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Europe
- 7.4.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. UK
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Germany
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Switzerland
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. France Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Japan
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. China
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. South Korea
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. South Korea Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Rest of the World
- 7.6.1. Rest of the World Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024
8.4. Participant's Overview
- 8.4.1. Amgen Inc.
  - 8.4.1.1. Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. Novartis AG
  - 8.4.2.1. Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. Gilead Sciences, Inc.
  - 8.4.3.1. Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Strategic Initiatives
- 8.4.4. bluebird bio, Inc.
  - 8.4.4.1. Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. Bristol-Myers Squibb Company
  - 8.4.5.1. Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. Legend Biotech.
  - 8.4.6.1. Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. Nanjing IASO Biotechnology
  - 8.4.7.1. Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. JW Therapeutics
  - 8.4.8.1. Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. CARsgen Therapeutics
  - 8.4.9.1. Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. Krystal Biotech, Inc.
  - 8.4.10.1. Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Strategic Initiatives

Product Code: GVR-4-68039-984-2

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 4 Global cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 5 Global cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 6 Global cancer gene therapy market, by region, 2018 - 2030 (USD Million)
Table 7 North America cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 8 North America cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 9 North America cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 10 North America cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 11 U.S. cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 12 U.S. cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 13 U.S. cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 14 Canada cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 15 Canada cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 16 Canada cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 17 Mexico cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 18 Mexico cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 19 Mexico cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 20 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 21 Europe cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 22 Europe cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 23 Europe cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 24 UK cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 25 UK cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 26 UK cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 27 Germany cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 28 Germany cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 29 Germany cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 30 Switzerland cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 31 Switzerland cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 32 Switzerland cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 33 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 34 Asia Pacific cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 35 Asia Pacific cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 36 Asia Pacific cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 37 Japan cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 38 Japan cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 39 Japan cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 40 China cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 41 China cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 42 China cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 43 South Korea cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 44 South Korea cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 45 South Korea cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 46 Rest of the world cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 47 Rest of the world cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 48 Rest of the world cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 49 Participant's overview
Table 50 Financial performance
Table 51 Key companies undergoing expansions
Table 52 Key companies undergoing acquisitions
Table 53 Key companies undergoing collaborations
Table 54 Key companies launching new products
Table 55 Key companies undertaking other strategies

List of Figures

Fig. 1 Cancer gene therapy market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Market outlook
Fig. 8 Segment snapshot
Fig. 9 Competitive landscape snapshot
Fig. 10 Parent market outlook
Fig. 11 Cancer gene therapy market driver analysis
Fig. 12 Cancer gene therapy market restraint analysis
Fig. 13 Cancer gene therapy market: Porter's analysis
Fig. 14 Cancer gene therapy market: PESTEL analysis
Fig. 15 Cancer gene therapy market: Indication outlook and key takeaways
Fig. 16 Cancer gene therapy market: Indication market share analysis, 2024 - 2030
Fig. 17 Global cancer gene therapy by large B-cell lymphoma market, 2018 - 2030 (USD Million)
Fig. 18 Global cancer gene therapy by multiple myeloma market, 2018 - 2030 (USD Million)
Fig. 19 Global cancer gene therapy by Acute Lymphoblastic Leukemia (ALL) market, 2018 - 2030 (USD Million)
Fig. 20 Global cancer gene therapy by melanoma (lesions) market, 2018 - 2030 (USD Million)
Fig. 21 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
Fig. 22 Cancer gene therapy market: Route of administration outlook and key takeaways
Fig. 23 Cancer gene therapy market: Route of administration market share analysis, 2024 - 2030
Fig. 24 Global cancer gene therapy by intravenous market, 2018 - 2030 (USD Million)
Fig. 25 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
Fig. 26 Cancer gene therapy market: Vector type outlook and key takeaways
Fig. 27 Cancer gene therapy market: Vector type market share analysis, 2024 - 2030
Fig. 28 Global cancer gene therapy by lentivirus market, 2018 - 2030 (USD Million)
Fig. 29 Global cancer gene therapy by retrovirus & gamma retrovirus market, 2018 - 2030 (USD Million)
Fig. 30 Global cancer gene therapy by AAV market, 2018 - 2030 (USD Million)
Fig. 31 Global cancer gene therapy by modified herpes simplex virus market, 2018 - 2030 (USD Million)
Fig. 32 Global cancer gene therapy by adenovirus market, 2018 - 2030 (USD Million)
Fig. 33 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 North America cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 U.S. cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Canada cancer gene therapy market, 2018 - 2030 (USD Million)
Fig. 38 Mexico cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Europe cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 UK cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Germany cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Switzerland cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Asia-Pacific cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Japan cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 China cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 South Korea cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Rest of the world cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Key company categorization
Fig. 49 Company market positioning
Fig. 50 Market participant categorization
Fig. 51 Strategy framework

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Indication, By Vector Type, By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030

Description

Table of Contents

List of Tables

Cancer Gene Therapy Market Growth & Trends:

Cancer Gene Therapy Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Cancer Gene Therapy Market: Indication Business Analysis

Chapter 5. Cancer Gene Therapy Market: Route of Administration Business Analysis

Chapter 6. Cancer Gene Therapy Market: VectorType Business Analysis

Chapter 7. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Indication, Route of Administration, & Vector Type

Chapter 8. Competitive Landscape

List of Tables

List of Figures